Pages that link to "Q33871210"
Jump to navigation
Jump to search
The following pages link to Prognostic impact of RAS mutations in patients with myelodysplastic syndrome (Q33871210):
Displaying 11 items.
- Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes (Q36770211) (← links)
- MEK1 is required for the development of NRAS-driven leukemia (Q37696978) (← links)
- I walk the line: how to tell MDS from other bone marrow failure conditions (Q38235622) (← links)
- The molecular pathogenesis of the myelodysplastic syndromes (Q38341998) (← links)
- RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma (Q38782798) (← links)
- Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights (Q39069357) (← links)
- Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool (Q39100115) (← links)
- Screening of mutations in the additional sex combs like 1, transcriptional regulator, tumor protein p53, and KRAS proto-oncogene, GTPase/NRAS proto-oncogene, GTPase genes of patients with myelodysplastic syndrome (Q41530601) (← links)
- Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. (Q42660774) (← links)
- Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. (Q50900611) (← links)
- Prognostic impact of RAS-pathway mutations in patients with myelofibrosis (Q90813121) (← links)